Skip to content

Pivotal Trial of the Boomerang Catheter for pDVA

Pivotal Multicenter Trial of the Boomerang® Catheter for Percutaneous Deep Vein Arterialization (pDVA)

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06311773
Enrollment
120
Registered
2024-03-15
Start date
2024-04-16
Completion date
2030-03-31
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Limb-Threatening Ischemia

Brief summary

The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.

Interventions

DEVICEBoomerang Catheter

The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.

Sponsors

Aveera Medical, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient is age ≥ 18 years 2. Patient has confirmed clinical diagnosis of Rutherford Category (RC) 5 or 6 Chronic Limb-Threatening Ischemia (CLTI) with previous angiogram or hemodynamic evidence (e.g., ABI ≤ 0.39, TP / TcPO2 \< 30 mm Hg) demonstrating severely diminished arterial perfusion of the index limb. 3. Assessment by the PI and an Independent Review Committee (IRC) determines that patient has no option for conventional distal bypass, surgical or endovascular therapy for limb salvage. 4. Inflow artery criteria: • Imaging confirmation of patent inflow artery (\< 50% stenosis) from Aortic bifurcation to tibial trifurcation. 5. Target conduit vein criteria: • Duplex ultrasound confirms that vein is free from thrombus, contiguous from the intended anastomosis site through the lateral plantar vein, and ≥ 2.0mm lumen-lumen diameter (with tourniquet applied) throughout. 6. Patient may be scheduled for a planned minor amputation (toe, ray, or trans-metatarsal) within 30 days after index procedure. 7. Prior stent(s) to inflow arteries (i.e., Iliac, SFA, Popliteal) are allowed. 8. Patient is willing and able to provide written informed consent. 9. Patient meets institutional criteria for procedure clearance and is able to comply with study requirements per PI judgement. 10. Diabetic patients have adequate glycemic control per investigator judgement. 11. Female patients of childbearing potential have a negative pregnancy test within 7 days prior to index procedure (urine) 12. Patient is enrolled in a wound care network and has an adequate support network to ensure compliance with medication regimen and follow-up study visits. 13. PI determines that the primary wound is stable (e.g., not rapidly deteriorating or showing signs of healing).

Exclusion criteria

1. Life expectancy \< 12 months. 2. Patient has a lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle). 3. Patient is dialysis dependent. 4. Significant acute or chronic kidney disease with a serum creatinine of \> 2.5 mg/dl in patients not undergoing dialysis. 5. Prior peripheral arterial bypass procedure on index limb within 30 days. 6. Previous major amputation of the target limb or absence of adequate viable tissue for below-ankle (e.g., mid-foot) amputation. 7. Patient is non-ambulatory due to above-ankle amputation of contralateral limb. 8. The patient is currently participating in another investigational drug or device study that has not completed the primary endpoint and that clinically interferes with the endpoints of this study per PI judgement. 9. Patient has known hypersensitivity or contraindication to materials used during the procedure (cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers) or a known contrast sensitivity that cannot be adequately pre-medicated. 10. Patient cannot be adequately treated with study medications due to known contraindication to aspirin, ADP antagonists such clopidogrel, prasugrel or ticagrelor, or anticoagulants such as heparin or bivalirudin. 11. Patient has had a stroke within the previous 3 months with residual Rankin score of ≥ 2. 12. NYHA Class IV heart failure which may compromise patient's ability to safely undergo a percutaneous procedure, per PI judgment.

Design outcomes

Primary

MeasureTime frameDescription
Amputation Free Survival (AFS)6-monthsFreedom from above-ankle amputation of the index limb or death (any cause) at 6 months, compared to a literature derived performance goal.

Secondary

MeasureTime frameDescription
Technical successDuring index procedureSuccessful deployment of the Boomerang Catheter to the anastomosis site, creation of an anastomosis, and confirmation of fistula flow using angiography or Doppler ultrasound immediately post catheter activation.
Procedural successImmediately post index procedureconfirmation of retrograde fistula flow in the target tibial vein conduit at index procedure completion.
Limb salvage3 years post index procedureFreedom from above-ankle amputation of the index limb.
Primary patency1 year post index procedureTime from fistula creation to the first intervention to maintain or reestablish flow through the fistula or to fistula occlusion.
Primary assisted patency1 year post index procedureTime from fistula creation to the first occlusion of the fistula.
Secondary patency1 year post index procedureTime from fistula creation to abandonment (e.g., decision to decline intervention due to occlusion) of the fistula.
Target wound healing1, 3, 6, 9-months, and 1-yearComplete or in-process healing of the patient's target wound(s).
Complete wound healing1, 3, 6, 9-months, and 1-yearComplete healing of all the patient's ischemic wound(s) in the index limb.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026